In the complex landscape of oncology, few malignancies present as formidable a challenge as those affecting the biliary tract. Characterized by their aggressive clinical course and often late-stage diagnosis, cholangiocarcinoma and gallbladder cancer remain significant global health concerns. In a strategic effort to consolidate the latest scientific breakthroughs and clinical strategies, Expert Review of Gastroenterology & Hepatology—a flagship journal under the Taylor & Francis umbrella—has officially launched a call for submissions for a specialized Article Collection: “Biliary Cancer Prevention and Treatment.”
This initiative aims to bridge the gap between laboratory discovery and bedside application, inviting researchers, surgeons, and multidisciplinary specialists to contribute to a comprehensive resource that could redefine the standard of care for patients worldwide.
I. Main Facts: Addressing the Biliary Challenge
Biliary tract cancers (BTCs), including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder carcinoma, have historically been considered "orphan" or rare cancers. However, recent epidemiological data suggest a shifting landscape, with rising incidence rates globally.
The Expert Review of Gastroenterology & Hepatology collection is designed to be a definitive repository of current knowledge. The journal is soliciting a wide range of content types, including:
- Original Research: Peer-reviewed studies presenting novel clinical, translational, or experimental data.
- Comprehensive Reviews: Critical syntheses of current literature that provide clarity on rapidly evolving therapeutic landscapes.
- Drug Profiles: Detailed analyses of emerging pharmacotherapies, including targeted agents and immunotherapy.
- Editorials: Concise, high-impact perspectives on the future direction of the field.
By focusing on molecular profiling, early detection, and systemic therapies, the collection intends to move beyond traditional surgical approaches and embrace the era of precision oncology.
II. Chronology: The Evolution of Biliary Tract Oncology
The history of biliary cancer treatment is marked by a transition from palliative, late-stage intervention to the contemporary era of molecularly driven, multimodal therapy.
The Era of Surgical Nihilism (1980s–2000s)
For decades, biliary cancers were synonymous with poor prognosis. Surgical resection remained the only potentially curative option, yet most patients presented with unresectable disease. Treatment was largely limited to systemic chemotherapy (often gemcitabine-based), which offered only modest survival benefits.
The Molecular Revolution (2010s)
The last decade transformed the field. The mapping of the biliary cancer genome revealed distinct "actionable" mutations—specifically FGFR2 fusions, IDH1 mutations, and HER2 amplifications. This shift in understanding allowed researchers to pivot from "one-size-fits-all" chemotherapy to targeted molecular therapies.
The Current Landscape (2020–Present)
We are currently in a period of unprecedented innovation. The FDA approval of several targeted therapies and the integration of checkpoint inhibitors (immunotherapy) into standard care regimens have significantly altered the trajectory for many patients. The Expert Review of Gastroenterology & Hepatology Article Collection arrives at this critical juncture, serving as a platform to document these rapid-fire successes and identify the obstacles that remain.
III. Supporting Data: The Clinical Imperative
The urgency of this call for papers is underscored by clinical statistics and the burgeoning potential of translational medicine.
Molecular Profiling as a New Standard
Recent data indicate that nearly 40% of patients with cholangiocarcinoma harbor a targetable genomic alteration. This is a staggering shift from the era where these cancers were treated as a monolithic entity. The upcoming Article Collection seeks to highlight:
- Liquid Biopsies: The development of circulating tumor DNA (ctDNA) assays for early detection and longitudinal monitoring of treatment resistance.
- Genomic Heterogeneity: Research into why primary tumors and metastases often exhibit different molecular profiles, complicating treatment decisions.
Surgical Innovation
While systemic therapy dominates the current narrative, the journal emphasizes that surgical excellence remains paramount. Innovations in liver transplantation protocols for select cholangiocarcinoma patients, coupled with advanced laparoscopic and robotic techniques, have expanded the pool of patients eligible for curative intent surgery.
IV. Official Responses and Industry Engagement
The launch of this collection has been met with enthusiasm from the medical community, particularly among hepatobiliary surgeons and medical oncologists who have long sought a centralized forum for high-impact biliary research.
Olivia Clovis-Corbett, the Commissioning Editor for this project at Taylor & Francis, has emphasized that the goal of this collection is not merely to publish research, but to foster a community. "We are looking for work that challenges the status quo," Clovis-Corbett stated in internal briefings. "The goal is to provide clinicians with a evidence-based toolkit that translates molecular insights into tangible improvements in patient survival and quality of life."
The editorial board of Expert Review of Gastroenterology & Hepatology is actively seeking submissions that span the globe, ensuring that the collection reflects the geographic disparities in cancer prevalence—such as the higher rates of biliary cancers in East Asia compared to the West—and the varying approaches to care that follow.
V. Implications: Shaping the Future of Patient Care
The implications of this Article Collection extend far beyond the pages of a medical journal. By curating this information, Taylor & Francis is facilitating a paradigm shift in how we approach one of the most difficult cancers to treat.
Implications for Clinical Practice
For the frontline clinician, the primary benefit is access to curated, state-of-the-art strategies. As new drugs move through the pipeline, keeping pace with efficacy and safety data becomes nearly impossible without structured summaries. This collection will provide the necessary peer-reviewed evidence to support clinical decision-making.
Implications for Research and Development
By highlighting "gaps" in current knowledge, the collection serves as a roadmap for future research. If the submitted articles collectively identify a lack of progress in, for example, immunotherapy resistance, it creates a clear signal for the scientific community and funding bodies to prioritize that specific area of inquiry.
Improving Patient Outcomes
Ultimately, the success of this collection will be measured by its impact on patients. The integration of early detection biomarkers, the application of personalized drug profiles, and the refinement of surgical techniques are all aimed at a singular goal: shifting the survival curve. Patients diagnosed with aggressive biliary malignancies deserve therapies based on the most current, rigorous, and multidisciplinary research available.
How to Participate
The invitation is extended to all researchers, clinical trial investigators, and specialists in the field of hepatobiliary health. Contributors are encouraged to reach out to the Commissioning Editor, Olivia Clovis-Corbett, to discuss potential topics, confirm the relevance of their research, and receive guidance on the submission process.
In a field where time is of the essence, the dissemination of high-quality, actionable knowledge is a clinical necessity. The Expert Review of Gastroenterology & Hepatology stands ready to provide the stage for the next generation of biliary cancer breakthroughs.
For further information or to submit your manuscript, please visit the official Taylor & Francis Article Collection portal.
Summary of Key Focus Areas for Prospective Authors:
- Molecular Profiling: Data on FGFR, IDH, and other targetable mutations.
- Early Detection: Advances in biomarkers and diagnostic imaging (MRCP, EUS).
- Systemic Therapy: Outcomes related to new-generation checkpoint inhibitors and targeted oral agents.
- Surgical Techniques: Case studies and trials regarding advanced resection and transplant criteria.
- Translational Research: Bridging the gap between laboratory models (organoids/xenografts) and human clinical trials.
The medical community is currently at a turning point in the battle against biliary cancer. Through this Article Collection, the Expert Review of Gastroenterology & Hepatology invites you to be a part of the progress that will define the next decade of oncological care.
About the Author
